Shares of Johnson & Johnson (NYSE:JNJ) rose in early trading on Wednesday, after the company reported upbeat third-quarter results. Here are some key analyst takeaways: RBC Capital Markets analyst Trung Huynh maintained an Outperform rating, while cutting the price target from $290 to $280.
Guggenheim Securities analyst Vamil Divan reiterated a Buy rating on the stock. Check out other analyst stock ratings.
RBC Capital Markets: While the sell-off inJohnson & Johnson’s shares, despite the company delivering in-line quarterly results and raising its guidance, seems "excessive," it sets "a negative tone for the broader Pharma sector," Huynh said in a note. The LIBREXIA-STROKE study results are expected this year, and the LIBREXIA-AF trial remains on track for the first quarter of 2027, the analyst stated.
The drug Darzalex underperformed in the third-quarter due to lower pricing outside the US, although the actual volume of drug sales remains strong, he added. 52 per share, Divan said.
19, respectively, he added. Investors are likely to be disappointed with some of the sales upside being driven by older products like Stelara and Simponi, with Tremfya and Tecvayli being "the only newer and strategically important products that appear to have meaningfully beat expectations," the analyst wrote.
Results from MedTech, especially the Cardiovascular segment and Abiomed, were also "somewhat disappointing," he further stated. 60 at the time of publication on Wednesday.
Read Also: Stock of the Day: Is this the Bottom for Johnson & Johnson?
